[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:beta-thalassemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":147,"states":148},"Beta Thalassemia",22,17,[8,16,22,29,35,40,47,54,60,66,72,78,84,90,96,102,108,114,121,127,134,140],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT02675959","Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease",[12],"Phase 2","RECRUITING","2026-08-26T02:17:35.666428Z","2026-07-30T01:46:14.457868Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04143724","Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia",[12],"2026-08-26T02:18:15.214990Z","2026-07-19T19:36:05.115181Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07599176","Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors",[26],"Phase 1\u002FPhase 2","2026-08-26T02:15:14.574786Z","2026-07-19T19:36:05.076207Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04008368","Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels",[26],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:29.409863Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":14,"content_modified":39},"NCT06364774","ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia",[26],"2026-05-05T02:43:26.949908Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":45,"content_modified":46},"NCT06647979","Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies",[44],"Phase 1","2026-08-26T02:16:49.565137Z","2026-05-05T02:43:26.921831Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT05477563","Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease",[51],"Phase 3","2026-08-26T02:15:59.318403Z","2026-05-05T02:43:26.772734Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05736419","A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)",[12],"2026-08-26T02:16:24.135291Z","2026-04-29T02:57:57.147275Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT04064060","A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials",[51],"2026-08-26T02:16:58.658552Z","2026-05-05T02:43:28.876012Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT04099966","AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha\u002FBeta T Cell and CD19+ B Cell Depletion",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:28.713058Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06271512","A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel",[],"2026-08-26T02:17:10.213717Z","2026-05-13T02:55:06.429924Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05799118","Study of the Role of Genetic Modifiers in Hemoglobinopathies",[],"2026-08-26T02:18:34.622081Z","2026-05-13T02:55:06.377334Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT04671212","Discarded Bone Marrow for Hematology Research",[],"2026-08-26T02:19:17.380174Z","2026-05-13T02:55:06.258466Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT03937817","Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants",[],"2026-08-26T02:16:44.178623Z","2026-05-13T02:55:06.180937Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06539169","FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases",[],"2026-08-26T02:18:44.395098Z","2026-05-13T02:55:06.551987Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT04416178","Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders",[],"2026-08-26T02:17:07.954622Z","2026-05-13T02:55:06.250218Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06872333","Allo HSCT for High Risk Hemoglobinopathies",[12],"2026-08-26T02:18:51.833592Z","2026-07-05T05:32:16.699778Z",{"nct_id":115,"title":116,"phases":117,"status":118,"updated_at":119,"content_modified":120},"NCT06664541","Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:13.426928Z","2026-06-16T05:54:07.764373Z",{"nct_id":122,"title":123,"phases":124,"status":118,"updated_at":125,"content_modified":126},"NCT04208529","A Long-term Follow-up Study in Participants Who Received CTX001",[51],"2026-08-26T02:15:28.524219Z","2026-07-05T18:42:10.722278Z",{"nct_id":128,"title":129,"phases":130,"status":131,"updated_at":132,"content_modified":133},"NCT06421636","A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:38:13.938630Z","2026-05-05T02:43:29.663533Z",{"nct_id":135,"title":136,"phases":137,"status":131,"updated_at":138,"content_modified":139},"NCT03655223","Early Check: Expanded Screening in Newborns",[],"2026-08-03T03:53:57.297126Z","2026-06-16T05:54:07.977837Z",{"nct_id":141,"title":142,"phases":143,"status":144,"updated_at":145,"content_modified":146},"NCT05635266","Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives",[],"UNKNOWN","2026-08-03T02:15:56.082035Z","2026-05-13T02:55:06.368062Z",[],[149,153,157,161,165,168,172,175],{"state":150,"count":151,"slug":152},"New York",9,"new-york",{"state":154,"count":155,"slug":156},"California",6,"california",{"state":158,"count":159,"slug":160},"Tennessee",5,"tennessee",{"state":162,"count":163,"slug":164},"Massachusetts",4,"massachusetts",{"state":166,"count":163,"slug":167},"Pennsylvania","pennsylvania",{"state":169,"count":170,"slug":171},"Maryland",3,"maryland",{"state":173,"count":170,"slug":174},"North Carolina","north-carolina",{"state":176,"count":170,"slug":177},"Texas","texas"]